Detrol La is a drug owned by Upjohn Us 2 Llc. It is protected by 7 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be May 11, 2020. Details of Detrol La's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US6911217 (Pediatric) | Controlled release bead, a method of producing the same and multiple unit formulation comprising it |
May, 2020
(4 years ago) |
Expired
|
|
US6630162 (Pediatric) | Pharmaceutical formulation and its use |
May, 2020
(4 years ago) |
Expired
|
|
US6770295 (Pediatric) | Therapeutic formulation for administering tolterodine with controlled release |
Feb, 2020
(4 years ago) |
Expired
|
| US6630162 | Pharmaceutical formulation and its use |
Nov, 2019
(5 years ago) |
Expired
|
| US6911217 | Controlled release bead, a method of producing the same and multiple unit formulation comprising it |
Nov, 2019
(5 years ago) |
Expired
|
| US6770295 | Therapeutic formulation for administering tolterodine with controlled release |
Aug, 2019
(5 years ago) |
Expired
|
|
US5382600 (Pediatric) | 3,3-diphenylpropylamines and pharmaceutical compositions thereof |
Sep, 2012
(12 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Detrol La's patents.
Latest Legal Activities on Detrol La's Patents
Given below is the list of recent legal activities going on the following patents of Detrol La.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Post Issue Communication - Certificate of Correction | 13 Oct, 2005 | US6911217 (Litigated) |
| Patent Issue Date Used in PTA Calculation Critical | 28 Jun, 2005 | US6911217 (Litigated) |
| Recordation of Patent Grant Mailed Critical | 28 Jun, 2005 | US6911217 (Litigated) |
| Issue Notification Mailed Critical | 08 Jun, 2005 | US6911217 (Litigated) |
| Receipt into Pubs | 24 May, 2005 | US6911217 (Litigated) |
| Dispatch to FDC | 23 May, 2005 | US6911217 (Litigated) |
| Receipt into Pubs | 12 May, 2005 | US6911217 (Litigated) |
| Receipt into Pubs | 26 Jan, 2005 | US6911217 (Litigated) |
| Application Is Considered Ready for Issue Critical | 25 Jan, 2005 | US6911217 (Litigated) |
| Dispatch to FDC | 25 Jan, 2005 | US6911217 (Litigated) |
US patents provide insights into the exclusivity only within the United States, but Detrol La is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Detrol La's family patents as well as insights into ongoing legal events on those patents.
Detrol La's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Detrol La's generic launch date based on the expiry of its last outstanding patent is estimated to be May 11, 2020 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Detrol La Generic API suppliers:
Tolterodine Tartrate is the generic name for the brand Detrol La. 15 different companies have already filed for the generic of Detrol La, with Unichem having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Detrol La's generic
How can I launch a generic of Detrol La before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Detrol La's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Detrol La's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Detrol La -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 2 mg and 4 mg | 30 Jul, 2007 | 1 | 22 Nov, 2016 | 11 Nov, 2019 | Extinguished |
Alternative Brands for Detrol La
Detrol La which is used for managing symptoms of overactive bladder and urinary incontinence., has several other brand drugs using the same active ingredient (Tolterodine Tartrate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Upjohn |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Tolterodine Tartrate, Detrol La's active ingredient. Check the complete list of approved generic manufacturers for Detrol La
About Detrol La
Detrol La is a drug owned by Upjohn Us 2 Llc. It is used for managing symptoms of overactive bladder and urinary incontinence. Detrol La uses Tolterodine Tartrate as an active ingredient. Detrol La was launched by Upjohn in 2000.
Approval Date:
Detrol La was approved by FDA for market use on 22 December, 2000.
Active Ingredient:
Detrol La uses Tolterodine Tartrate as the active ingredient. Check out other Drugs and Companies using Tolterodine Tartrate ingredient
Treatment:
Detrol La is used for managing symptoms of overactive bladder and urinary incontinence.
Dosage:
Detrol La is available in capsule, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 4MG | CAPSULE, EXTENDED RELEASE | Prescription | ORAL |
| 2MG | CAPSULE, EXTENDED RELEASE | Prescription | ORAL |